{"classes":[{"categories":[{"measurements":[{"comment":"NA = t½ and its corresponding geometric coefficient of variation were not calculated due to insufficient samples in the terminal phase to estimate lambda\\_z.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"NA = Geometric coefficient of variation values were not reported when N \\< 2.","groupId":"OG001","spread":"NA","value":"2.46"},{"groupId":"OG002","spread":"73.9","value":"3.69"},{"groupId":"OG003","spread":"34.7","value":"11.2"},{"groupId":"OG004","spread":"23.6","value":"11.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"t½ was defined as the time required to divide the MK-0482 plasma concentration by two after reaching pseudo-equilibrium. Blood samples were collected pre-dose and post-dose at designated timepoints to determine t½ of MK-0482.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \\[Q3W\\]) for up to 35 cycles (approximately 24 months).","id":"OG000","title":"MK-0482 7.5 mg Q3W"},{"description":"Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG001","title":"MK-0482 25 mg Q3W"},{"description":"Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG002","title":"MK-0482 75 mg Q3W"},{"description":"Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG003","title":"MK-0482 225 mg Q3W"},{"description":"Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG004","title":"MK-0482 750 mg Q3W"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention, were compliant with the study procedures, and had available data from at least 1 treatment dose were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre-dose and Days 1, 2, 4, 8, and 15 post-dose. Cycle=21 days.","title":"Plasma Elimination Terminal Half-life (t½) of MK-0482","type":"SECONDARY","unitOfMeasure":"Days"}